A sequencing add-on service integrating targeted NGS, whole-exome or whole-genome sequencing, and bulk or single-cell RNA-seq with ex vivo drug-response data generated from matched aliquots of the same primary patient specimen.
Sequencing alone describes biology; combined with measured functional response, it enables prediction of drug sensitivity. We integrate mutational and expression profiles with ex vivo drug-response data from matched aliquots of the same specimen — revealing candidate biomarkers and resistance mechanisms that genotype alone cannot resolve.
Targeted NGS panels, whole-exome sequencing, and whole-genome sequencing, with annotated variants, variant allele frequencies, affected genes, and predicted functional impact.
Bulk RNA-seq with differential gene expression, pathway analysis, and cluster identification; and single-cell RNA-seq for cell-state resolution, population clustering, and UMAP visualization.
Correlate genotype and gene-expression profiles with measured ex vivo drug response to identify candidate biomarkers and inform biomarker-enrichment and study-design hypotheses.
Incorporate genomic and transcriptomic profiling with matched aliquots from the same primary specimen. This integrated method is especially valuable for Biomarker Validation and Drug-Resistance Profiling.
Key Deliverables
A scientist — not a sales desk — will scope a tailored study and return a design and timeline.
